A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2023-03-02
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-03-29 (study day 17); relationship: not assessed
mild
assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-04-17 (study day 36); relationship: not assessed
moderate
assessed
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-07-21 (study day 131); relationship: N
Data queries
No data queries.